Asthma is a chronic inflammatory condition of the lung airways resulting in episodic airflow obstruction. This chronic inflammation heightens the twitchiness of the airways—airways hyper responsiveness (AHR)—to provocative exposures. Asthma management is aimed at reducing airways inflammation by minimizing proinflammatory environmental exposures, using daily controller anti-inflammatory medications, and controlling co-morbid conditions that can worsen asthma. Less inflammation typically leads to better asthma control, with fewer exacerbations and decreased need for quick-reliever asthma medications. Nevertheless, exacerbations can still occur. Early intervention with systemic corticosteroids greatly reduces the severity of such episodes. Advances in asthma management and, especially, pharmacotherapy enable all but the uncommon child with severe asthma to live normally.

**Etiology**

Although the cause of childhood asthma has not been determined, contemporary research implicates a combination of environmental exposures and inherent biologic and genetic vulnerabilities. Respiratory exposures in this causal environment include inhaled allergens, respiratory viral infections, and chemical and biologic air pollutants such as environmental tobacco smoke. In the predisposed host, immune responses to these common exposures can be a stimulus for prolonged, pathogenic inflammation and aberrant repair of injured airways tissues. Lung dysfunction (i.e., AHR and reduced airflow) develops. These pathogenic processes in the growing lung during early life adversely affect airways growth and differentiation, leading to altered airways at mature ages. Once asthma has developed, ongoing exposures appear to worsen it, driving disease persistence and increasing the risk of severe exacerbations.

**Genetics**

More than 100 genetic loci have been linked to asthma. Although the genetic linkages to asthma have sometimes differed between cohorts, asthma has been consistently linked with loci containing proallergic, proinflammatory genes (the interleukin [IL]-4 gene cluster on chromosome 5). Genetic variation in receptors for different asthma medications is associated with variation in biologic response to these medications (polymorphisms in the β2-adrenergic receptor). Other candidate genes include ADAM-33 (member of the metalloproteinase family), the gene for the prostanoid DP receptor, and genes located on chromosome 5q31 (possibly IL-12).

**Environment**

Recurrent wheezing episodes in early childhood are associated with common respiratory viruses, including respiratory syncytial virus, rhinovirus, influenza virus, adenovirus, parainfluenza virus, and human metapneumovirus. This association implies that host features affecting immunologic host defense, inflammation, and the extent of airways injury from ubiquitous viral pathogens underlie susceptibility to recurrent wheezing in early childhood. Furthermore, injurious viral infections of the airways that manifest as pneumonia or bronchiolitis.
requiring hospitalization are risk factors for persistent asthma in childhood. Other airways exposures can also exacerbate ongoing airways inflammation, increase disease severity, and drive asthma persistence. Indoor and home allergen exposures in sensitized individuals can initiate airways inflammation and hypersensitivity to other irritant exposures, and are strongly linked to disease severity and persistence. Consequently, eliminating the offending allergen(s) can lead to resolution of asthma symptoms and can sometimes “cure” asthma. Environmental tobacco smoke and air pollutants (ozone, sulfur dioxide) aggravate airways inflammation and increase asthma severity. Cold dry air and strong odors can trigger bronchoconstriction when airways are irritated but do not worsen airways inflammation or hyper responsiveness.

**Epidemiology**

Asthma is a common chronic disease, causing considerable morbidity. Nearly 60% of those with current asthma, had experienced at least one asthma attack in the prior year. Boys (14% vs 10% girls) and children in poor families (16% vs 10% not poor) are more likely to have asthma. Worldwide, childhood asthma appears to be increasing in prevalence, despite considerable improvements in our management and pharmacopeia to treat asthma. Worldwide, childhood asthma appears to be increasing in prevalence, the prevalence of current wheeze, 0.8-37.6%.

Approximately 80% of all asthmatic patients report disease onset prior to 6 yr of age. However, of all young children who experience recurrent wheezing, only a minority goes on to have persistent asthma in later childhood. Prediction of asthma includes major (parent asthma, eczema, inhalant allergen sensitization) and minor (allergic rhinitis, wheezing apart from colds, ≥4% eosinophil, food allergen sensitization) risk factors. Allergy in young children has emerged as a major risk factor for the persistence of childhood asthma.

**CHILDHOOD RISK FACTORS FOR PERSISTENT ASTHMA**

**Parental asthma**

**Allergy:**
- Atopic dermatitis (eczema)
- Allergic rhinitis
- Food allergy
- Inhalant allergen sensitization
- Food allergen sensitization

**Severe lower respiratory tract infection:**
- Pneumonia
- Bronchiolitis requiring hospitalization

**Wheezing apart from colds**
- Male gender
- Low birth weight
- Environmental tobacco smoke exposure
- Possible use of acetaminophen (paracetamol)
- Exposure to chlorinated swimming pools:
- Reduced lung function at birth

**Types of Childhood Asthma**

There are 2 main types of childhood asthma:

(1) Recurrent wheezing in early childhood, primarily triggered by common viral infections of the respiratory tract.
(2) Chronic asthma associated with allergy that persists into later childhood and often adulthood. A 3rd type of childhood asthma typically emerges in females who experience obesity and early-onset puberty (by 11 yrs. of age).

**Pathogenesis**

Airflow obstruction in asthma is the result of numerous pathologic processes. In the small airways, airflow is regulated by smooth muscle encircling the airways lumens; bronchoconstriction of these bronchiolar muscular bands restricts or blocks airflow. A cellular inflammatory infiltrate and exudates distinguished by eosinophils, but also including other inflammatory cell types (neutrophils, monocytes, lymphocytes, mast cells, basophils), can fill and obstruct the airways and induce epithelial damage and desquamation into the airways lumen. Helper T lymphocytes and other immune cells that produce proallergic, proinflammatory cytokines (IL-4, IL-5, IL-13), and chemokine's (exotoxins) mediate this inflammatory process. Pathogenic immune responses and inflammation may also result from a breach in normal immune regulatory processes (such as regulatory T lymphocytes that produce IL-10 and transforming growth factor [TGF]-β) that dampen effector immunity and inflammation when they are no longer needed. Hypersensitivity or susceptibility to a variety of provocative exposures or triggers can lead to airways inflammation, AHR, edema, basement membrane thickening, sub epithelial collagen deposition, smooth muscle and mucous gland hypertrophy, and mucus hyper secretion—all processes that contribute to airflow obstruction.

**ASTHMA TRIGGERS**

Common viral infections of the respiratory tract
Aeroallergens in sensitized asthmatic patients:
- Animal dander
- Indoor allergens
- Dust mites
- Cockroaches
- Molds

Seasonal aeroallergens:
- Pollens (trees, grasses, weeds)
- Seasonal molds

Environmental tobacco smoke
Air pollutants:
- Ozone
- Sulfur dioxide
- Particulate matter
- Wood- or coal-burning smoke
- Endotoxin, mycotoxins
- Dust

Strong or noxious odors or fumes:
- Perfumes, hairsprays
- Cleaning agents

Occupational exposures:
Farm and barn exposures
Formaldehydes, cedar, paint fumes
Cold air, dry air
Exercise
Crying, laughter, hyperventilation
Co-morbid conditions :
  Rhinitis
  Sinusitis
  Gastro esophageal reflux

Clinical Manifestations

Intermittent dry coughing and expiratory wheezing are the most common chronic symptoms of asthma. Older children and adults report associated shortness of breath and chest tightness; younger children are more likely to report intermittent, non-focal chest pain. Respiratory symptoms can be worse at night, especially during prolonged exacerbations triggered by respiratory infections or inhalant allergens. Daytime symptoms, often linked with physical activities or play, are reported with greatest frequency in children. Other asthma symptoms in children can be subtle and nonspecific, including self-imposed limitation of physical activities, general fatigue (possibly due to sleep disturbance), and difficulty keeping up with peers in physical activities. Asking about previous experience with asthma medications (bronchodilators) may provide a history of symptomatic improvement with treatment that supports the diagnosis of asthma. Lack of improvement with bronchodilator and corticosteroid therapy is inconsistent with underlying asthma and should prompt more vigorous consideration of asthma-masquerading conditions.

Asthma symptoms can be triggered by numerous common events or exposures

The presence of risk factors, such as a history of other allergic conditions (allergic rhinitis, allergic conjunctivitis, atopic dermatitis, food allergies), parental asthma, and/or symptoms apart from colds, supports the diagnosis of asthma. During routine clinic visits, children with asthma commonly present without abnormal signs, emphasizing the importance of the medical history in diagnosing asthma. Some may exhibit a dry, persistent cough. The chest findings are often normal. Deeper breaths can sometimes elicit otherwise undetectable wheezing. In clinic, quick resolution (within 10 min) or convincing improvement in symptoms and signs of asthma with administration of a short-acting inhaled β-agonist (SABA; e.g., albuterol) is supportive of the diagnosis of asthma.

During asthma exacerbations, expiratory wheezing and a prolonged expiratory phase can usually be appreciated by auscultation. Decreased breath sounds in some of the lung fields, commonly the right lower posterior lobe, are consistent with regional hypoventilation owing to airways obstruction. Crackles (or rales) and rhonchi can sometimes be heard, resulting from excess mucus production and inflammatory exudate in the airways. The combination of segmental crackles and poor breath sounds can indicate lung segmental atelectasis that is difficult to distinguish from bronchial pneumonia and can complicate acute asthma management. In severe exacerbations, the greater extent of airways obstruction causes labored breathing and respiratory distress, which manifests as inspiratory and expiratory wheezing, increased prolongation of exhalation, poor air entry, suprasternal and intercostal retractions, nasal flaring, and accessory respiratory muscle use. In extremis, airflow may be so limited that wheezing cannot be heard
Differential Diagnosis
Many childhood respiratory conditions can present with symptoms and signs similar to those of asthma. Besides asthma, other common causes of chronic, intermittent coughing include gastro esophageal reflux (GER) and rhino sinusitis. Both GER and chronic sinusitis can be challenging to diagnose in children. Often, GER is clinically silent in children, and children with chronic sinusitis do not report sinusitis-specific symptoms, such as localized sinus pressure and tenderness. In addition, both GER and rhino sinusitis are often co-morbid with childhood asthma and, if not specifically treated, may make asthma difficult to manage.

DIFFERENTIAL DIAGNOSIS OF CHILDHOOD ASTHMA

UPPER RESPIRATORY TRACT CONDITIONS
- Allergic rhinitis
- Chronic rhinitis
- Sinusitis
- Adenoidal or tonsillar hypertrophy
- Nasal foreign body

MIDDLE RESPIRATORY TRACT CONDITIONS
- Laryngotraceobronchomalacia
- Laryngotraceobronchitis (e.g., pertussis)
- Laryngeal web, cyst, or stenosis
- Vocal cord dysfunction
- Vocal cord paralysis
- Tracheoesophageal fistula
- Vascular ring, sling, or external mass compressing on the airway (e.g., tumor)
- Foreign body aspiration
- Chronic bronchitis from environmental tobacco smoke exposure
- Toxic inhalations

LOWER RESPIRATORY TRACT CONDITIONS
- Bronchopulmonary dysplasia (chronic lung disease of preterm infants)
- Viral bronchiolitis
- Gastro esophageal reflux

Causes of bronchiectasis:
- Cystic fibrosis
- Immune deficiency
- Allergic bronchopulmonary mycoses (e.g., aspergillosis)
- Chronic aspiration
- Immotile cilia syndrome, primary ciliary dyskinesia
- Bronchiolitis obliterans
- Interstitial lung diseases
- Hypersensitivity pneumonitis
Pulmonary eosinophilia, Churg-Strauss vasculitis
Pulmonary hemosiderosis
Tuberculosis
Pneumonia
Pulmonary edema (e.g., congestive heart failure)
Medications associated with chronic cough:
Acetyl cholinesterase inhibitors
B-Adrenergic antagonists
Angiotensin-converting enzyme inhibitors

**Diagnosis**
The diagnosis depends on the clinical presentations + laboratory findings.

**Lung functions tests**
Measuring of the expiratory air flow is helpful in the diagnosis, monitoring & assessing the efficacy of treatment.

a) Spirometer (usually for children >6 yrs.): It measures FEV1 (forced expiratory volume in 1 second) & FVC (forced vital capacity). It also assesses the "bronchodilator response" using inhaled B-agonist, the "exercise challenge", & the "bronchoprovocation challenges" using methacoline, histamine, or cold & dry air which is rarely used.

b) Peak expiratory flow (PEF) monitoring: It is a simple & inexpensive home used tool to measure the peak expiratory flow (PEF).

**Lung functions abnormality in asthma**

Spirometer
1. Air flow limitation (ΔFEV1, FEV1 / FVC ratio < 0.8)
2. Bronchodilator response →improvement in FEV1 ≥12%
3. Exercise response →worsening in FEV1 ≥15%
PEF morning to afternoon variability ≥20%

**Radiology**
CXR may be normal apart from the hyperinflation. Subtle and nonspecific findings of hyperinflation (flattening of the diaphragms) and per bronchial thickening. There may be a features of complications & sometimes CT-scan can be used (e.g. bronchiectasis).

**Others**
As allergy testing & IgE level may help in the management & prognosis.
In severe exacerbation: blood gas analysis, blood PH.

**Classification of asthma severity**
1. **Acute exacerbation:** It is classified into 3 grades: mild, moderate, & severe acute attack (exacerbation) according to the following parameters: PEFR, PR, Alertness, Dyspnea, Pulsus paradoxus, Accessory muscle use, Color, Auscultation, O2 saturation, & PCO2.
2. **Chronic asthma:** It is classified into 4 grades: Mild intermittent asthma, Mild persistent asthma, Moderate persistent asthma, & Severe persistent asthma according to the following variables: Daytime symptoms, Nocturnal symptoms, Exacerbations, Lung functions, & B-agonists use.
Asthma medications

1. Quick-relief medications (relievers)
   - Short-acting inhaled B-agonists: as albuterol (ventolin) & terbutaline.
   - Inhaled anticholinergic: as ipratropium bromide & atropine.
   - Short course systemic glucocorticoids: as prednisone & methylprednisolone.

2. Long term-control medications (controllers)
   - NSAI agents: as cromolyn & nedocromil.
   - Inhaled glucocorticoids: as beclomethasone & budesonide.
   - Sustained-release theophylline.
   - Long-acting inhaled B-agonists (LABA S): as salmetrol.
   - Leukotriene modifiers: as monteleukast & zafirleukast.
   - Oral glucocorticoids: as prednisone & methylprednisolone.

Management

Management of the acute attack (exacerbation)
   - Mild attack can be treated at home.
   - Indications of hospital admission
     1. Moderate-severe attack which does not improve within 1-2 hrs of initial treatment.
     2. Prolonged symptoms before admission.
     3. Inadequate access to the medical care & medications.
     4. Difficult psychological conditions.
     5. Difficulty in obtaining transportation to the hospital in event of further deterioration.

Home management
   - Immediate inhaled short acting B-agonist (up to 3 times / 1 hr.).
   - Good response is characterized by: resolution of symptoms in 1 hr., no further symptoms over the next 4 hrs. & improvement of PEF of 80% predicted or personal best.
   - If the child has incomplete response to B-agonist (i.e. persistent symptoms &/or PEF of 60-80% of predicted or personal best) → short course of oral glucocorticoids (e.g. prednisone 1-2 mg/kg/day for 4 days) in addition to inhaled B-agonist.

Hospital management
   - O2 administration.
   - Close monitoring of the clinical status.
   - Inhaled short acting B-agonist (every 20 min. for 1 hr.).
   - If necessary, systemic glucocorticoids (prednisolone 2 mg/kg/day oral or IV). [NAEPP recommends the use of methylprednisolone at 1 mg/kg/dose every 6 hrs. for 2 days then ↓ dose to 1-2 mg/kg/day in 2 divided doses until PEF reaches 70% of predicted or personal best. This is especially useful in the very severe attacks of asthma].
   - Inhaled ipratropium bromide may be added to B-agonist if no significant response is seen with 1st inhaled B-agonist.
   - Subcutaneous epinephrine may be given in severe cases.
   - IV fluid may be given in persistent severe dyspnea (slightly below maintenance due to ↑ ADH).
In status asthmatics, the following options may be added:
1. Intubation & mechanical ventilation.
2. IV B-agonist, IV theophylline.
3. Inhaled Heliox (Helium & O2).
4. IV Mg sulfate (smooth muscle relaxant).

Patient may be discharged home if there are:
1. Sustained improvement in symptoms.
2. Normal physical findings.
3. PEF > 70% of predicted or personal best.
4. O2 saturation > 92% on room air for 4 hrs.

Discharge therapy includes inhaled B-agonist (up to ever 3-4 hrs.) + glucocorticoids (3-7 days course of prednisolone).

Management of chronic asthma
1. Mild intermittent asthma
   There is no continuous daily treatment but inhaled short acting B-agonist can be used when there are symptoms or as prophylactic therapy for exercises.
   ✓ Daily treatment with a "controller" drug is recommended for all 3 types of persistent asthma:

2. Mild persistent asthma
   ✓ Low-dose inhaled glucocorticoid
   ✓ Inhaled cromolyn
   ✓ Leukotriene modifier
   ✓ [Sustained-release theophylline (as alternative)].

3. Moderate persistent asthma
   ✓ Medium-dose inhaled glucocorticoid
   ✓ Low-dose inhaled glucocorticoid + either LABA inhaler or leukotrien modifier, or [Sustained-release theophylline or LABA tab. (as alternative)].

4. Severe persistent asthma
   ✓ High-dose inhaled glucocorticoid + either LABA inhaler or leukotrien modifier, or [sustained-release theophylline or LABA tab. (as alternative)] +
   ✓ Oral glucocorticoid (if needed).

Prognosis

Recurrent coughing and wheezing occurs in 35% of preschool-aged children. Of these, approximately one third continue to have persistent asthma into later childhood, and approximately two thirds improve on their own through their teen years. Asthma severity by the ages of 7-10 yrs. of age is predictive of asthma persistence in adulthood. Children with moderate to severe asthma and with lower lung function measures are likely to have persistent asthma as adults. Children with milder asthma and normal lung function are likely to improve over time, with some becoming periodically asthmatic (disease-free for months to years); however, complete remission for 5 yrs. in childhood is uncommon.
Prevention

Several non pharmacotherapeutic measures with numerous positive health attributes—avoidance of environmental tobacco smoke (beginning prenatally), prolonged breastfeeding (>4 mo.), an active lifestyle, and a healthy diet—might reduce the likelihood of asthma development. Immunizations are currently not considered to increase the likelihood of development of asthma; therefore, all standard childhood immunizations are recommended for children with asthma, including varicella and annual influenza vaccines.